GlobeNewswire Inc.T3·15mo ago
CLRB Cellectar Biosciences INC NEW
XNAS
3.37
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CLRB
$3.37
—
Key stats
$3.37
Pre-market
$1.23
+1.61%
- 52-Week Range
- $1.12 – $4.70
- YTD
- -2.88%
- Straddle Price
- $2.38
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.0B
- Open
- $1.25
- Day Range
- $1.19 – $1.27
- Volume
- 184,736
- Prev Close
- $1.22
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.46 |
| Cost of Equity (CAPM) | 11.91% (VRP-adj) |
| WACC | 12.06% |
| Volatility Risk Premium | -87.8pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -74.7% |
| Book / Price | 415.6% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.99 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.42 |
| Bollinger Width / SMA20 | 4917.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$5.05
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $17.65 | 20% | median 3.5× · 3 peers |
| Peer P/S | n/a | 0% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $1.99 | 80% | stability 80% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 11
- List Date
- 2005-04-19
- CIK
- 0001279704
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.46) (2 est.)
- Headquarters
- Florham Park, NJ
- Homepage
- https://www.cellectar.com
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC p…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -8.21% | -15.48% | -7.36% | 36.71% | -22.62% | -7.20% | -4.03% |
| Feb | -6.53% | -19.48% | 2.63% | -0.25% | 10.50% | 3.02% | -1.69% |
| Mar | -15.71% | 36.41% | -13.33% | -5.24% | 14.16% | -15.05% | 0.21% |
| Apr | -7.06% | -22.45% | 5.48% | -21.17% | -13.84% | 4.00% | -9.17% |
| May | -1.20% | -22.79% | -1.27% | -2.22% | -3.48% | 16.73% | -2.37% |
| Jun | -26.54% | -1.08% | 19.63% | -15.25% | -9.58% | -6.40% | -6.54% |
| Jul | -6.84% | -4.79% | -4.41% | -15.69% | -0.41% | -7.22% | -6.56% |
| Aug | -3.77% | 45.08% | -10.61% | 6.80% | 3.18% | -5.64% | 5.84% |
| Sep | -12.74% | -35.38% | 45.05% | 0.00% | 16.18% | -25.20% | -2.02% |
| Oct | -5.20% | -39.88% | -15.38% | -1.92% | -41.25% | -35.29%* | -23.15% |
| Nov | -24.07% | -6.93% | 3.78% | -24.14% | 8.79% | -- | -8.51% |
| Dec | 0.59% | -6.04% | 7.78% | -80.33% | -20.91% | -- | -19.78% |
| Total | -72.37% | -74.20% | 20.43% | -88.88% | -55.71% | -60.89% | -55.27% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.42
SMA 50: $1.99
SMA 200: $2.68
Current: $1.21
EMA 12: $1.29
EMA 26: $1.54
MACD: -0.2421 | Signal: 0.0154
BEARISH
ADX (14): 36.25
TREND
+DI: 16.52
−DI: 27.86
Momentum Oscillators
RSI (14): 28.64
OVERSOLD
Stoch %K: 13.96
Stoch %D: 13.72
Williams %R: -82.00
Volume & Volatility
BB Upper: $1.92
BB Lower: $0.92
NEUTRAL
OBV: 62,881,396
Vol SMA 20: 170,903
Vol ROC: -1.24%
ATR: $0.13
True Range: $0.08
HV 20: 93.4%
HV 30: 87.8%
HV 60: 67.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Market volatility, technical signals, and recent news headlines driving stock price fluctuations.
Primary Risks: High market volatility, potential catalysts, and regulatory developments affecting the biotech sector.
Investment Thesis: CLRB's stock performance is influenced by its beta value (1.62), indicating high volatility compared to the broader market. The company's recent news highlights demand for BTK inhibitors in the Waldenstrom Macroglobulinemia space. However, the stock's technical indicators suggest a neutral trend, and options activity indicates bullish sentiment.
Recent News Sentiment Impact: Positive headlines (1, 2) about advancements in the biotech sector contribute to CLRB's recent price movement. The negative news headline (3) regarding financial restatement may have had some impact on investor confidence.
Technical Analysis
Trend Direction: Neutral (Short-term: neutral, Medium-term: range-bound, Long-term: trending upward)
Support/Resistance Levels:
- Upper Bollinger Band: $2.68
- Middle Line: $2.51
- Lower Bollinger Band: $2.34
- SMA 20: $2.51
Momentum Signals:
- RSI (14): 36.76 (neutral)
- MACD: -0.05 / Signal: -0.02 / Histogram: -0.03 (bearish)
Volume Analysis: Volume rate of change (152.65%) suggests increasing interest, but OBV remains relatively stable.
News & Sentiment Analysis
Recent Headlines Summary: CLRB's recent news highlights demand for BTK inhibitors in Waldenstrom Macroglobulinemia and compliance with regulatory filings.
Sentiment Assessment: Aggregate news sentiment is positive (70%).
Catalyst Identification: Upcoming events include a key opinion leader event to review CLOVER WaM pivotal trial results and market landscape, which may impact investor confidence.
Risk & Volatility Assessment
Beta Interpretation: CLRB's beta value (1.62) indicates high risk relative to the broader market.
Volatility Regime: High volatility regime suggests increased uncertainty and potential for significant price movements.
Options Market Signals:
- IV Rank: 0.0% (Low)
- Current IV: 0.0%
- Expected Move: $2.38
Downside Protection: Support levels include the Lower Bollinger Band ($2.34) and SMA 20 ($2.51).
Market Context & Positioning
Sector Performance: CLRB's performance is relatively strong within its sector.
Institutional Activity: Volume patterns suggest some institutional interest, but overall participation remains moderate.
Correlation Analysis: CLRB's stock moves more than the broader market (R-squared interpretation), indicating high volatility.
Relative Valuation: Positioning suggests CLRB may be undervalued relative to its peers and sector averages.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $2.68
- Middle Line: $2.51
- Lower Bollinger Band: $2.34
Breakout/Breakdown Levels: SMA 20 ($2.51) and Lower Bollinger Band ($2.34) are key levels to monitor.
Time-Sensitive Catalysts: Upcoming events, including the key opinion leader event, may impact investor confidence.
Risk Management: Stop-loss levels should be set around $2.30-2.35, with position sizing considering the high volatility regime and options market signals.
This report provides a comprehensive analysis of CLRB's stock performance, incorporating technical indicators, news sentiment, risk metrics, and options activity. The neutral trend suggests caution, while recent positive headlines contribute to the bullish sentiment in the options market. High market volatility and regulatory developments remain primary risks, emphasizing the need for careful risk management and consideration of time-sensitive catalysts.
Generated
News
All CLRB news →
GlobeNewswire Inc.T3·24mo ago
GlobeNewswire Inc.T3·26mo ago
GlobeNewswire Inc.T3·28mo ago
GlobeNewswire Inc.T3·29mo ago
GlobeNewswire Inc.T3·29mo ago
GlobeNewswire Inc.T3·30mo ago
GlobeNewswire Inc.T3·30mo ago
GlobeNewswire Inc.T3·31mo ago
GlobeNewswire Inc.T3·31mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
7 of 7 under expected move
Avg Expected Move
186.70%
Avg Actual Move
7.78%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-03-27 | After-Close | 34.24% | 9.49% | 0.28x | Within |
| 2024-07-23 | Pre-Market | 30.63% | 18.54% | 0.61x | Within |
| 2024-11-18 | After-Close | 56.94% | 9.04% | 0.16x | Within |
| 2025-03-13 | Pre-Market | 813.07% | 5.37% | 0.01x | Within |
| 2025-05-13 | Pre-Market | 171.56% | 9.13% | 0.05x | Within |
| 2025-08-14 | After-Close | 127.26% | 1.81% | 0.01x | Within |
| 2025-11-13 | After-Close | 73.17% | 1.05% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CLRB Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $2.38
7-DTE Move: $2.38
Days to Exp: — (2026-02-20)
Options Flow
Call Volume: 102
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 5
Put OI: 0
P/C OI: —
Total OI: 5
ATM Options Pricing
ATM Call: $0.03
ATM Put: $2.35
Call %: 0.7%
Put %: 69.7%
Chain Summary
Chain Volume: 102
Chain OI: 5
Last Updated: 2/20/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Feb 3 · ATM 1971.7% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
as of Feb 3 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.38Feb 20
Beta Analysis
Risk Metrics
Beta: 1.5806
Alpha: -109.42%
Correlation: 0.2547
R-Squared: 6.5%
Stock Volatility: 79.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
CLRB Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 5,940,113 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
CLRB Insider Trading (Form 4)
Latest: 2026-07-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Stefan Loren | Grant (A) | +15,000 opt | — | EDGAR | ||
| 2026-07-08 | Asher Chanan-Khan | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-08 | Frederick W Driscoll | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-08 | John Neis | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-08 | James V Caruso | President & CEO | Grant (A) | +250,000 opt | — | EDGAR | |
| 2026-07-08 | Stefan Loren | Grant (A) | +15,000 opt | — | EDGAR | ||
| 2026-07-08 | Andrew Gu | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2026-07-08 | Douglas J Swirsky | Director | Grant (A) | +37,500 opt | — | EDGAR | |
| 2026-07-08 | Chad J Kolean | CFO | Grant (A) | +92,000 opt | — | EDGAR | |
| 2026-07-08 | Jarrod Longcor | Chief Operating Officer | Grant (A) | +118,000 opt | — | EDGAR | |
| 2026-05-11 | Jarrod Longcor | Chief Operating Officer | Buy (P) | +8,680 | $2.88 | $25.0K | EDGAR |
| 2026-05-11 | James V Caruso | Chief Executive Officer | Buy (P) | +8,680 | $2.88 | $25.0K | EDGAR |
| 2025-12-16 | John Neis | Director | Sell (S) | −198 | $3.70 | -$732 | EDGAR |
| 2025-07-03 | Jarrod Longcor | Chief Operating Officer | Buy (P) | +10,000 | $4.99 | $49.9K | EDGAR |
| 2025-07-03 | James V Caruso | Chief Executive Officer | Buy (P) | +10,000 | $4.99 | $49.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CLRB Insider Holdings
6 insiders · @ $1.21
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jarrod Longcor | Chief Operating Officer | 20,451 | $24.7K | $83.3K | 9 | 2026-07-08 |
| 2 | James V Caruso | President & CEO | 20,318 | $24.6K | $74.9K | 8 | 2026-07-08 |
| 3 | Chad J Kolean | CFO | 6,418 | $7.8K | $24.9K | 7 | 2026-07-08 |
| 4 | Douglas J Swirsky | Director | 83 | $100 | $26.0K | 7 | 2026-07-08 |
| 5 | Frederick W Driscoll | Director | 65 | $79 | $20.2K | 7 | 2026-07-08 |
| 6 | John Neis | Director | 10 | $12 | -$732 | 7 | 2026-07-08 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CLRB Board & Officers
As of SEC filings through Jul 10, 2026Directors 6
- John Neis · since Aug 14, 2014
- James V Caruso · since Jun 15, 2015
- Douglas J Swirsky · since Apr 10, 2017
- Frederick W Driscoll · since Apr 10, 2017
- Asher Chanan-Khan · since Jun 23, 2021
- Andrew Gu · since May 18, 2026
Officers 3
- James V Caruso · Chief Executive Officer · listed since Jul 2025
- Chad J Kolean · Chief Financial Officer · listed since Feb 2022
- Jarrod Longcor · Chief Operating Officer · listed since Jan 2023
Changes in the last 10 years (20)
| May 18, 2026 | Andrew Gu became a director |
| May 17, 2026 | The company announced the departure of Stefan Loren from the board in an SEC filing |
| Jul 3, 2025 | James V Caruso listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Feb 15, 2023 | Andrei Shustov became Senior Vice President, Medical |
| Jan 18, 2023 | Jarrod Longcor listed as Chief Operating Officer (previously Chief Business Officer) in SEC filings |
| Nov 21, 2022 | Darrell Shane Lea became Chief Commercial Officer |
| Feb 24, 2022 | Chad J Kolean listed as Chief Financial Officer (previously VP, CFO and Treasurer) in SEC filings |
| Feb 22, 2022 | The company announced the departure of Dov Elefant as Chief Financial Officer in an SEC filing |
| Nov 1, 2021 | The company announced the departure of John E. Friend II as VP, Chief Medical Officer in an SEC filing |
| Jun 23, 2021 | Asher Chanan-Khan became a director |
| Jan 6, 2020 | Igor D Grachev became Chief Medical Officer |
| Sep 10, 2019 | Dov Elefant became Chief Financial Officer |
| Mar 9, 2019 | Charles Thomas Bernhardt III became Interim CFO |
| Apr 1, 2018 | Brian M Posner became Chief Financial Officer |
| Sep 25, 2017 | Jarrod Longcor listed as Chief Business Officer (previously Sr. VP of Corp Dev & Ops) in SEC filings |
| Sep 5, 2017 | John P. Hamill became Interim CFO |
| Apr 17, 2017 | John E. Friend II became VP, Chief Medical Officer |
| Apr 10, 2017 | Frederick W Driscoll became a director |
| Apr 10, 2017 | Douglas J Swirsky became a director |
| Nov 1, 2016 | Richard Hertzberg reported in an SEC filing no longer being a 10% owner |
Not reported recently (7)
- Darrell Shane Lea · Last reported as Chief Commercial Officer in an SEC filing dated Jun 18, 2024
- Andrei Shustov · Last reported as Senior Vice President, Medical in an SEC filing dated Jun 18, 2024
- Stephen A Hill · Last reported as a director in an SEC filing dated Jun 25, 2020
- Igor D Grachev · Last reported as Chief Medical Officer in an SEC filing dated Jan 8, 2020
- Charles Thomas Bernhardt III · Last reported as Interim CFO in an SEC filing dated Mar 11, 2019
- Brian M Posner · Last reported as Chief Financial Officer in an SEC filing dated Jan 18, 2019
- John P. Hamill · Last reported as Interim CFO in an SEC filing dated Sep 8, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold CLRB
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.59
TTM Revenue
$0.00
TTM Net Income
$-22.32M
TTM Op. Cash Flow
$-19.47M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $0.00 | $-6.93M | $-0.57 | $-6.01M |
| Q1 '26 | 2026-03-31 | — | $-5.65M | $-1.33 | $-4.85M |
| Q4 '25 | 2025-12-31 | — | $-5.30M | $-0.53 | $-4.34M |
| Q3 '25 | 2025-09-30 | — | $-4.44M | $-1.41 | $-4.28M |
| Q2 '25 | 2025-06-30 | $0.00 | $-5.45M | $-3.39 | $-5.12M |
| Q1 '25 | 2025-03-31 | — | $-6.60M | $-4.30 | $-9.38M |
| Q4 '24 | 2024-12-31 | — | $-2.36M | $-0.10 | $-10.91M |
| Q3 '24 | 2024-09-30 | — | $-14.66M | $-12.13 | $-9.17M |
| Q2 '24 | 2024-06-30 | — | $-919.37K | $-5.43 | $-14.14M |
| Q1 '24 | 2024-03-31 | — | $-26.64M | $-27.30 | $-13.36M |
| Q4 '23 | 2023-12-31 | — | $-7.88M | $-12.30 | $-9.60M |
| Q3 '23 | 2023-09-30 | — | $-17.52M | $-46.50 | $-8.07M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.24
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-74.7%
ROA
-60.9%
Div Yield
0.00%
FCF Yield
-270.96%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$7.19M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
166.26K
SI % of Float
1.86%
Days to Cover
2.05
Short Vol Ratio
51.1%
Free Float
8.95M
Float %
94.7%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-19